Skip to main content

Table 1 HLA alleles associated with carbamazepine-induced cutaneous adverse drug reactions

From: Personalizing carbamazepine therapy

Population Target allele Type of cADR Selectivity in casesa Odds ratio Reference
Han Chinese in Taiwan HLA-B*1502 SJS-TEN 59/60 1,357 [7]
   HSS 0/13 - [7]
   MPE 1/18 - [7]
  HLA-A*3101 SJS-TEN 1/60 - [7]
   HSS 2/13 - [7]
   MPE 6/18 17.5 [7]
Japanese HLA-A*3101 SJS-TEN 5/6 33.9 [9]
   DIHS 21/36 9.5 [9]
   Other 19/35 8.0 [9]
European HLA-A*3101 SJS-TEN 5/12 25.93 [5]
   HSS 10/27 12.41 [5]
   MPE 23/106 8.33 [5]
Thai HLA-B*1502 SJS-TEN 37/42 54.76 [10]
Malaysian HLA-B*1502 SJS-TEN 12/16 16.15 [11]
  1. aNumber of patients with the target allele/number of patients with type of cADR. cADR, cutaneous adverse drug reaction; DIHS, drug-induced hypersensitivity syndrome; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.